Boonton, NJ – June 13, 2017 – Enteris BioPharma, Inc., Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, today announced that Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, will present at the 2017 BIO International Convention (BIO 2017) being held June 19-22, 2017, at the San Diego Convention Center, San Diego CA.
Mr. Tune will present Enteris’ corporate growth strategy and its focus on developing orally delivered peptide therapeutics for a broad range of treatment indications. Since its founding in 2013, Enteris has advanced multiple internal and external programs leveraging its Peptelligence® platform to enable the safe delivery of peptide-based therapeutics with low oral bioavailability.
Event: 2017 BIO International Convention
Date: Wednesday, June 21, 2017
Time: 3:00 p.m. (Pacific Time)
Location: Diego Convention Center – Company Presentation Theater 2
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. The Company’s proprietary oral delivery technology – Peptelligence® – has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Additionally, Enteris BioPharma is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma’s most advanced internal product candidate, Ovarest® (oral leuprolide tablet), is a Phase 2a-ready oral peptide, being developed for the treatment of endometriosis. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit http://www.EnterisBioPharma.com.
|For Enteris BioPharma:||Enteris Media Relations:|
|Brian Zietsman, President & CFO|
|Jason Rando / Andrew Mielach|
Tiberend Strategic Advisors, Inc.